keyword
MENU ▼
Read by QxMD icon Read
search

Multiple myeloma AND imaging

keyword
https://www.readbyqxmd.com/read/28218709/pet-imaging-for-initial-staging-and-therapy-assessment-in-multiple-myeloma-patients
#1
REVIEW
Clément Bailly, Rodolphe Leforestier, Bastien Jamet, Thomas Carlier, Mickael Bourgeois, François Guérard, Cyrille Touzeau, Philippe Moreau, Michel Chérel, Françoise Kraeber-Bodéré, Caroline Bodet-Milin
Multiple myeloma (MM) is a hematological neoplasm characterized by the clonal proliferation of malignant plasma cells in the bone marrow. MM results in diffuse or focal bone infiltration and extramedullary lesions. Over the past two decades, advances have been made with regard to the diagnosis, staging, treatment, and imaging of MM. Computed tomography (CT) and magnetic resonance imaging (MRI) are currently recommended as the most effective imaging modalities at diagnostic. Yet, recent data from the literature suggest that positron emission tomography combined with computed tomography (PET/CT) using (18)F-deoxyglucose (FDG) is a promising technique for initial staging and therapeutic monitoring in this pathology...
February 18, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28203342/optimizing-current-and-emerging-therapies-in-multiple-myeloma-a-guide-for-the-hematologist
#2
REVIEW
Shahzad Raza, Rachael A Safyan, Evan Rosenbaum, Alex S Bowman, Suzanne Lentzsch
Multiple myeloma (MM) is the second most common hematologic malignancy. The diagnosis of MM requires ⩾10% clonal plasma cells in the bone marrow or biopsy-proven plasmacytoma, plus evidence of end-organ damage (hypercalcemia, renal failure, anemia, and lytic bone lesions). The definition of MM has recently been expanded to include a ⩾60% clonal plasma cell burden in the bone marrow, serum involved/uninvolved light chain ratio of ⩾100, or more than one focal lesion on magnetic resonance imaging ⩾5 mm in the absence of end-organ damage...
February 2017: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/28194051/consensus-in-the-management-of-multiple-myeloma-in-india-at-myeloma-state-of-the-art-2016-conference
#3
REVIEW
Uday Yanamandra, Navin Khattry, Shaji Kumar, Noopur Raje, Arihant Jain, Sundar Jagannath, Hari Menon, Lalit Kumar, Neelam Varma, Subhash Varma, Tapan Saikia, Pankaj Malhotra
The science of multiple myeloma (MM) and related plasma cell disorders is rapidly evolving with increased understanding of the disease biology and recent approval of the newer drugs widening the therapeutic armamentarium. Despite multiple international guidelines regarding the management of this disease, the practice of managing MM is not uniform amongst Indian physicians. There are challenges in management which are unique to the Indian patients. This review discusses these challenges and the consensus of the nation-wide experts in dealing with the same...
March 2017: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/28188075/bisphosphonate-related-osteonecrosis-and-metastasis-within-the-same-site-of-the-jaw
#4
Alessandro Corsi, Claudio Ungari, Mara Riminucci, Alessandro Agrillo
Bisphosphonates (BPs) bind selectively to hydroxyapatite and accumulate in sites of active bone remodeling, where they inhibit bone turnover by interfering with osteoclastic recruitment, activity, and survival. For this reason, they are used in oncologic patients to prevent, decrease, and delay potentially life-threatening skeletal-related complications associated with multiple myeloma (MM) and metastasis, including hypercalcemia, pain, and pathologic fractures. Despite substantial benefits, treatment with BPs can be associated with the development of osteonecrosis of the jaw (ONJ), a pathologic condition for which pathophysiologic mechanisms are not completely defined and current criteria for prevention, diagnosis, and management are based largely on expert recommendations and guidelines...
January 18, 2017: Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/28151709/progress-and-paradigms-in-multiple-myeloma
#5
EDITORIAL
Kenneth C Anderson
Remarkable progress has been achieved in multiple myeloma, and patient median survival has been extended 3- to 4-fold. Specifically, there have been 18 newly approved treatments for multiple myeloma in the past 12 years, including seven in 2015, and the treatment paradigm and patient outcome have been transformed. The definition of patients benefitting from these therapies has been broadened. Response criteria now include minimal residual disease (MRD), assessed in bone marrow by multicolor flow cytometry or sequencing, and by imaging for extramedullary disease...
November 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28079810/risk-of-vertebral-compression-fractures-in-multiple-myeloma-patients-a-finite-element-study
#6
D Anitha, Baum Thomas, Kirschke S Jan, Karupppasamy Subburaj
The purpose of this study was to develop and validate a finite element (FE) model to predict vertebral bone strength in vitro using multidetector computed tomography (MDCT) images in multiple myeloma (MM) patients, to serve as a complementing tool to assess fracture risk. In addition, it also aims to differentiate MM patients with and without vertebral compression fractures (VCFs) by performing FE analysis on vertebra segments (T1-L5) obtained from in vivo routine MDCT imaging scans. MDCT-based FE models were developed from the in vitro vertebrae samples and were then applied to the in vivo vertebrae segments of MM patients (n = 4) after validation...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28072730/bortezomib-combined-with-lenalidomide-as-the-first-line-treatment-for-the-rare-synchronous-occurrence-of-multiple-myeloma-and-pulmonary-adenocarcinoma-a-case-report
#7
Wenli Zuo, Xinghu Zhu, Jingke Yang, Zhenyang Mei, Mei Deng, Quande Lin, Yongping Song, Qingsong Yin
BACKGROUND: Simultaneous multiple myeloma (MM) and pulmonary adenocarcinoma is a rare occurrence, and thus, treatment is a challenge. This study reports on 1 such case of MM with concurrent lung cancer, where an accurate diagnosis was made and the patient underwent treatment for both cancers. CASE SUMMARY: A 68-year-old man presented with 2 months of progressive lower back pain. Visualization with magnetic resonance imaging (MRI) revealed multiple collapsed vertebrae from T12 to S3, as well as an altered signal intensity at the T3 vertebra...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28060076/epibulbar-plasmacytoma-masquerading-as-subconjunctival-hemorrhage-in-a-patient-with-multiple-myeloma
#8
Amanda Bradley, Amy Estes, Lane Ulrich, Dilip Thomas, David Gay
PURPOSE: We report a 75-year-old woman with a history of multiple myeloma immunoglobulin D (IgD) variant, who presented with an epibulbar plasmacytoma masquerading as a subconjunctival hemorrhage. METHODS: Magnetic resonance imaging of the brain and orbits with and without contrast was obtained and surgical biopsy of the subconjunctival lesion was performed; histopathology confirmed the diagnosis of plasmacytoma. RESULTS: Subconjunctival biopsy revealed a plasma cell neoplasm infiltrate in the episcleral layer...
February 2017: Cornea
https://www.readbyqxmd.com/read/28042328/-68-ga-pentixafor-pet-ct-for-imaging-of-chemokine-receptor-cxcr4-expression-in-multiple-myeloma-comparison-to-18-f-fdg-and-laboratory-values
#9
Constantin Lapa, Martin Schreder, Andreas Schirbel, Samuel Samnick, Klaus Martin Kortüm, Ken Herrmann, Saskia Kropf, Herrmann Einsele, Andreas K Buck, Hans-Jürgen Wester, Stefan Knop, Katharina Lückerath
Chemokine (C-X-C motif) receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer including multiple myeloma (MM). Proof-of-concept of CXCR4-directed radionuclide therapy in MM has recently been reported. This study assessed the diagnostic performance of the CXCR4-directed radiotracer [(68)Ga]Pentixafor in MM and a potential role for stratifying patients to CXCR4-directed therapies. Thirty-five patients with MM underwent [(68)Ga]Pentixafor-PET/CT for evaluation of eligibility for endoradiotherapy...
2017: Theranostics
https://www.readbyqxmd.com/read/28028340/diffuse-large-b-cell-lymphoma-of-the-parotid-gland-cytological-histopathological-and-immunohistochemical-features-a-rare-case-report
#10
Sainath K Andola, Meenakshi M Masgal, Rajeev M Reddy
Primary malignant lymphomas of the salivary glands are rare, accounting for 2-5% of salivary gland tumors and 5% of extranodal lymphomas, frequently seen in the parotid gland. There are single case reports mentioned in the literature. Clinical presentation is not characteristic and the disease is often overlooked with delay in diagnosis and treatment. We are reporting a case of bilateral parotid gland lymphoma in a 55-year-old male, presented with bilateral enlarged parotids. Magnetic resonance imaging (MRI) showed bilateral enlarged parotid glands with multiple well-defined intraparotid lesions...
October 2016: Journal of Cytology
https://www.readbyqxmd.com/read/27983660/investigating-effects-of-proteasome-inhibitor-on-multiple-myeloma-cells-using-confocal-raman-microscopy
#11
Jeon Woong Kang, Surya P Singh, Freddy T Nguyen, Niyom Lue, Yongjin Sung, Peter T C So, Ramachandra R Dasari
Due to its label-free and non-destructive nature, applications of Raman spectroscopic imaging in monitoring therapeutic responses at the cellular level are growing. We have recently developed a high-speed confocal Raman microscopy system to image living biological specimens with high spatial resolution and sensitivity. In the present study, we have applied this system to monitor the effects of Bortezomib, a proteasome inhibitor drug, on multiple myeloma cells. Cluster imaging followed by spectral profiling suggest major differences in the nuclear and cytoplasmic contents of cells due to drug treatment that can be monitored with Raman spectroscopy...
December 14, 2016: Sensors
https://www.readbyqxmd.com/read/27941377/68ga-psma-pet-ct-imaging-in-multiple-myeloma
#12
Arun Sasikumar, Ajith Joy, M R A Pillai, Raviteja Nanabala, Boben Thomas
The potential applications of Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in the imaging of prostate cancer are now well established. A few case reports regarding the potential use of Ga-PSMA PET/CT in nonprostate cancer malignancies are also published. Apparently, the tumor neoangiogenesis is the mechanism attributed to increased Ga-PSMA uptake in the tumor sites in nonprostatic malignancies. We describe the use of Ga-PSMA PET/CT in imaging multiple myeloma. The intense Ga-PSMA avidity of the lesions also opens up the possibility of theranostics with Lu-PSMA...
February 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27917370/multiple-myeloma-like-spinal-mri-findings-in-skeletal-fluorosis-an-unusual-presentation-of-fluoride-toxicity-in-human
#13
Javed Ahsan Quadri, Mohd Meraj Alam, Saba Sarwar, Ashraf Ghanai, A Shariff, Taposh K Das
Endemic fluorosis is a worldwide environmental problem due to excessive fluoride, commonly due to increased drinking water fluoride levels but sometimes due to other sources such as food with high fluoride content. In India, 21 of the 35 states are known to have health problems associated with fluoride toxicity. The present report is a case of a 50-year-old female who was seen with progressive spinal complications and a MRI of the spine suggestive of multiple myeloma. The MRI of the lumbosacral spine showed a diffuse and heterogeneous marrow signal of the lower dorsal and lumbosacral vertebrae...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27917369/management-of-multiple-myeloma-and-usage-of-bortezomib-perspective-from-india-and-ukraine
#14
Amit Garg, Mykhaylo Morgunskyy, Yogesh Belagali, Namita Gupta, Shyam Prasad Akku
Novel treatment strategies have remarkably improved the multiple myeloma (MM) patients' survival, with associated increased costs. A joint panel meet of international experts from India and Ukraine was held in New Delhi on May 19, 2016 focusing on MM management, bortezomib role, unmet medical needs, and current challenges. The health-care system for oncology in India is majorly private vs. government-based in Ukraine. In India, electrophoresis, serum-free light chain assays, bone marrow tests, and X-rays are available modes of diagnosis...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27900520/nuclear-medicine-imaging-of-multiple-myeloma-particularly-in-the-relapsed-setting
#15
REVIEW
Esther G M de Waal, Andor W J M Glaudemans, Carolien P Schröder, Edo Vellenga, Riemer H J A Slart
Multiple myeloma (MM) is characterized by a monoclonal plasma cell population in the bone marrow. Lytic lesions occur in up to 90 % of patients. For many years, whole-body X-ray (WBX) was the method of choice for detecting skeleton abnormalities. However, the value of WBX in relapsing disease is limited because lesions persist post-treatment, which restricts the capacity to distinguish between old, inactive skeletal lesions and new, active ones. Therefore, alternative techniques are necessary to visualize disease activity...
February 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27882113/peripheral-neuropathy-outcomes-and-efficacy-of-subcutaneous-bortezomib-when-combined-with-thalidomide-and-dexamethasone-in-the-treatment-of-multiple-myeloma
#16
Hong Liu, Ruirong Xu, Hongming Huang
Due to the safety, convenience and efficacy of subcutaneous administration of bortezomib (scBor), it is becoming increasingly common to treat multiple myeloma (MM) using this treatment method. The current retrospective study suggested a lower incidence of peripheral neuropathy (PN) outcomes and superior efficacy following treatment with scBor combined with thalidomide and dexamethasone (VTD) in MM when compared with intravenous Bor (ivBor) treatment. The data of 81 patients from the Affiliated Hospital of Nantong University between September 2011 and February 2014 were analyzed, including 37 scBor and 44 ivBor patients administered a median (range) of 5...
November 2016: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/27861307/epibulbar-plasmacytoma-masquerading-as-subconjunctival-hemorrhage-in-a-patient-with-multiple-myeloma
#17
Amanda Bradley, Amy Estes, Lane Ulrich, Dilip Thomas, David Gay
PURPOSE: We report a 75-year-old woman with a history of multiple myeloma immunoglobulin D (IgD) variant, who presented with an epibulbar plasmacytoma masquerading as a subconjunctival hemorrhage. METHODS: Magnetic resonance imaging of the brain and orbits with and without contrast was obtained and surgical biopsy of the subconjunctival lesion was performed; histopathology confirmed the diagnosis of plasmacytoma. RESULTS: Subconjunctival biopsy revealed a plasma cell neoplasm infiltrate in the episcleral layer...
November 16, 2016: Cornea
https://www.readbyqxmd.com/read/27842666/simplified-response-monitoring-criteria-for-multiple-myeloma-in-patients-undergoing-therapy-with-novel-agents-using-computed-tomography
#18
COMPARATIVE STUDY
Christoph Schabel, Marius Horger, Sara Kum, Katja Weisel, Jan Fritz, Sorin D Ioanoviciu, Georg Bier
INTRODUCTION: Multiple myeloma is a malignant hematological disorder of the mature B-cell lymphocytes originating in the bone marrow. While therapy monitoring is still mainly based on laboratory biomarkers, the additional use of imaging has been advocated due to inaccuracies of serological biomarkers or in a-secretory myelomas. Non-enhanced CT and MRI have similar sensitivities for lesions in yellow marrow-rich bone marrow cavities with a favourable risk and cost-effectiveness profile of CT...
December 2016: European Journal of Radiology
https://www.readbyqxmd.com/read/27816878/invasive-granulomatous-cryptococcal-sinusitis-in-an-adult-with-multiple-myeloma
#19
Richard A Ferraro, Jana Ivanidze, Elizabeth Margolskee, Hamilton Tsang, Theresa Sconomiglio, Yuliya S Jhanwar
We report a case of cryptococcal sinusitis, a rare presentation of Cryptococcus neoformans infection in a patient with multiple myeloma. The objective of this case report is to highlight the utility of structural and functional imaging modalities in the differential diagnosis of sinonasal soft tissue masses in the immunocompromised patient population. PET-CT was the first imaging modality in this patient, who presented for routine follow-up staging of multiple myeloma, and was asymptomatic at the time of his presentation...
January 2017: Clinical Imaging
https://www.readbyqxmd.com/read/27806731/in-vitro-assessment-of-a-computer-designed-potential-anticancer-agent-in-cervical-cancer-cells
#20
Michelle Helen Visagie, Seema Rummurat Jaiswal, Anna Margaretha Joubert
BACKGROUND: Computer-based technology is becoming increasingly essential in biological research where drug discovery programs start with the identification of suitable drug targets. 2-Methoxyestradiol (2ME2) is a 17β-estradiol metabolite that induces apoptosis in various cancer cell lines including cervical cancer, breast cancer and multiple myeloma. Owing to 2ME2's poor in vivo bioavailability, our laboratory in silico-designed and subsequently synthesized a novel 2ME2 analogue, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol), using receptor- and ligand molecular modeling...
November 2, 2016: Biological Research
keyword
keyword
67485
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"